Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)

Autor: Nakamura, Y., Namikawa, K., Yoshikawa, S., Kiniwa, Y., Maekawa, T., Yamasaki, O., Isei, T., Matsushita, S., Nomura, M., Nakai, Y., Fukushima, S., Saito, S., Takenouchi, T., Tanaka, R., Kato, H., Otsuka, A., Matsuya, T., Baba, N., Nagase, K., Inozume, T., Fujimoto, N., Kuwatsuka, Y., Onishi, M., Kaneko, T., Onuma, T., Umeda, Y., Ogata, D., Takahashi, A., Otsuka, M., Teramoto, Y., Yamazaki, N.
Zdroj: In ESMO Open December 2021 6(6)
Databáze: ScienceDirect